dc.contributor.author | Henjum, Kristi | |
dc.contributor.author | Almdahl, Ina S | |
dc.contributor.author | Årskog, Vibeke | |
dc.contributor.author | Minthon, Lennart | |
dc.contributor.author | Hansson, Oskar | |
dc.contributor.author | Fladby, Tormod | |
dc.contributor.author | Nilsson, Lars N G | |
dc.date.accessioned | 2016-05-03T04:41:15Z | |
dc.date.available | 2016-05-03T04:41:15Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Alzheimer's Research & Therapy. 2016 Apr 27;8(1):17 | |
dc.identifier.uri | http://hdl.handle.net/10852/50205 | |
dc.description.abstract | Background
Alzheimer’s disease (AD) neuropathology is associated with neuroinflammation, but there are few useful biomarkers. Mutant variants of triggering receptor expressed on myeloid cells 2 (TREM2) have recently been linked to late-onset AD and other neurodegenerative disorders. TREM2, a microglial receptor, is involved in innate immunity. A cleaved fragment, soluble TREM2 (sTREM2), is present in the cerebrospinal fluid (CSF).
Methods
We developed and used a novel enzyme-linked immunosorbent assay to investigate the potential value of CSF sTREM2 as an AD biomarker in two independent cohorts: an AD/mild cognitive impairment (MCI)/control cohort (n = 100) and an AD/control cohort (n = 50).
Results
We found no significant difference in sTREM2 levels between groups of controls and patients with AD or MCI. However, among all controls there was a positive correlation between sTREM2 and age (Spearman rho = 0.50; p < 0.001; n = 75). In the AD/MCI/control cohort, CSF sTREM2 correlated positively with total Tau (T-tau) (Spearman rho 0.57; p < 0.001; n = 50), phosphorylated Tau (P-tau) (Spearman rho 0.63; p < 0.001; n = 50) and amyloid-β1–42 (Aβ42) (Spearman rho 0.35; p = 0.01; n = 50) in control subjects. Among controls with a CSF Aβ42 above a cut-off value (700 pg/ml) in this cohort, the positive correlation between sTREM2 and Aβ42 was stronger (Spearman rho = 0.44; p = 0.002; n = 46).
Conclusions
sTREM2 in CSF correlates with aging in controls, and with the neurodegenerative markers CSF T-tau/P-tau among controls who are negative for AD CSF core biomarkers Aβ42, T-tau or P-tau. | |
dc.language.iso | eng | |
dc.rights | Henjum et al.; licensee BioMed Central Ltd. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease | |
dc.type | Journal article | |
dc.date.updated | 2016-05-03T04:41:16Z | |
dc.creator.author | Henjum, Kristi | |
dc.creator.author | Almdahl, Ina S | |
dc.creator.author | Årskog, Vibeke | |
dc.creator.author | Minthon, Lennart | |
dc.creator.author | Hansson, Oskar | |
dc.creator.author | Fladby, Tormod | |
dc.creator.author | Nilsson, Lars N G | |
dc.identifier.doi | http://dx.doi.org/10.1186/s13195-016-0182-1 | |
dc.identifier.urn | URN:NBN:no-53862 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/50205/1/13195_2016_Article_182.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | 17 | |